Publikationen 2006
Baum M, Ernst E, Lejeune S, Horneber M: Role of complementary and alternative medicine in the care of patients with breast cancer: report of the European Society of Mastology (EUSOMA) Workshop, Florence, Italy, December 2004. Eur J Cancer 2006; 42(12):1702-1710.
Baum M, Cassileth BR, Daniel R, Ernst E, Filshie J, Nagel GA, Horneber M, Kohn M, Lejeune S, Maher J, Terje R, Smith WB: The role of complementary and alternative medicine in the management of early breast cancer: recommendations of the European Society of Mastology (EUSOMA). Eur J Cancer 2006; 42(12):1711-1714.
Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl MG, Wandt H, Theuser C, Ehninger G, Zander AR: Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol 2006; 76(1):9-17.
de BS, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, Mediavilla JD, Recher C, Ades L, Quesnel B, Brault P, Fey M, Wandt H, Machover D, Guerci A, Maloisel F, Stoppa AM, Rayon C, Ribera JM, Chomienne C, Degos L, Fenaux P: Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 2006; 20(1):35-41.
Dennert G, Horneber M: Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev 2006; 3:CD005037.
Efficace F, Horneber M, Lejeune S, Van DF, Leering S, Rottmann M, Aaronson NK: Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology. J Clin Epidemiol 2006; 59(12):1257-1265.
Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P, Korfel A: Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006; 17(7):1141-1145.
Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hanel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108(13):4003-4008.
Glasmacher A, Cornely O, Ullmann AJ, Wedding U, Bodenstein H, Wandt H, Boewer C, Pasold R, Wolf HH, Hanel M, Dolken G, Junghanss C, Andreesen R, Bertz H: An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57(2):317-325.
Launso L, Drageset BJ, Fonnebo V, Jacobson JS, Haahr N, White JD, Salamonsen A, Horneber M, Egeland E: Exceptional disease courses after the use of CAM: selection, registration, medical assessment, and research. an international perspective. J Altern Complement Med 2006; 12(7):607-613.
Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschluter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschutz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG: Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006; 24(6):593-600.
Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W: Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006; 107(5):1014-1022.
Schwemmlein M, Peipp M, Barbin K, Saul D, Stockmeyer B, Repp R, Birkmann J, Oduncu F, Emmerich B, Fey GH: A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. Br J Haematol 2006; 133(2):141-151.
Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M: A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37(4):387-392.
